Safety and Efficacy of Otaplimastat in Patients with Acute Ischemic Stroke Requiring tPA (SAFE-TPA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study.

Jong S KimKyung Bok LeeJong-Ho ParkSang Min SungKyungmi OhEung-Gyu KimDae-Il ChangYang Ha HwangEun-Jae LeeWon-Ki KimChung JuByung Su KimJei-Man Ryunull null

Published in: Annals of neurology (2019)

Intravenous otaplimastat adjunctive therapy in patients receiving rtPA is feasible and generally safe. The functional efficacy of otaplimastat needs to be investigated with further large trials. ANN NEUROL 2020;87:233-245.

Keyphrases

double blind
placebo controlled
acute ischemic stroke
clinical trial
phase iii
phase ii
phase ii study
study protocol
high dose
atomic force microscopy
randomized controlled trial
stem cells
squamous cell carcinoma
mesenchymal stem cells
radiation therapy
mass spectrometry
cell therapy